120. Dash AK, Cudworth GC, 2nd. Therapeutic applica- tions of implantable drug delivery systems. J Pharmacol Toxicol Methods 1998; 40:1-12; PMID:9920528; http://dx.doi.org/10.1016/S1056-8719(98)00027-6. 121. Hua Y, Sahashi K, Hung G, Rigo F, Passini MA, Bennett CF, et al. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev 2010; 24:1634-44; PMID:20624852; http://dx.doi.org/10.1101/gad.1941310. 122. Hashizume R, Ozawa T, Gryaznov SM, Bollen AW, Lamborn KR, Frey WH, 2nd, et al. New thera- peutic approach for brain tumors: Intranasal deliv- ery of telomerase inhibitor GRN163. Neuro Oncol 2008; 10:112-20; PMID:18287341; http://dx.doi. org/10.1215/15228517-2007-052. 123. Michalon A, Sidorov M, Ballard TM, Ozmen L, Spooren W, Wettstein JG, et al. Chronic Pharmacological mGlu5 Inhibition Corrects Fragile X in Adult Mice. Neuron 2012; 74:49-56; PMID:22500629. 124. Waehler R, Russell SJ, Curiel DT. Engineering tar- geted viral vectors for gene therapy. Nat Rev Genet 2007; 8:573-87; PMID:17607305; http://dx.doi. org/10.1038/nrg2141. 125. Daemen T, de Mare A, Bungener L, de Jonge J, Huckriede A, Wilschut J. Virosomes for antigen and DNA delivery. Adv Drug Deliv Rev 2005; 57:451- 63; http://dx.doi.org/10.1016/j.addr.2004.09.005; PMID:15560951. 126. Ploegh HL. Viral strategies of immune evasion. Science 1998; 280:248-53; PMID:9535648; http://dx.doi. org/10.1126/science.280.5361.248. 127. Jiang Z, Zhao P, Zhou Z, Liu J, Qin L, Wang H. Using attenuated Salmonella typhi as tumor target- ing vector for MDR1 siRNA delivery. Cancer Biol Ther 2007; 6:555-60; PMID:17374987; http://dx.doi. org/10.4161/cbt.6.4.3850. 128. Zhang L, Ambulos N, Mixson AJ. DNA delivery to cells in culture using peptides. Methods Mol Biol 2004; 245:33-52; PMID:14707368. 129. Witte A, Wanner G, Sulzner M, Lubitz W. Dynamics of PhiX174 protein E-mediated lysis of Escherichia coli. Arch Microbiol 1992; 157:381-8; PMID:1534215; http://dx.doi.org/10.1007/BF00248685. 130. Kudela P, Paukner S, Mayr UB, Cholujova D, Schwarczova Z, Sedlak J, et al. Bacterial ghosts as novel efficient targeting vehicles for DNA delivery to the human monocyte-derived dendritic cells. J Immunother 2005; 28:136-43; PMID:15725957; http://dx.doi. org/10.1097/01.cji.0000154246.89630.6f. 131. Paukner S, Kohl G, Lubitz W. Bacterial ghosts as novel advanced drug delivery systems: antiproliferative activity of loaded doxorubicin in human Caco-2 cells. J Control Release 2004; 94:63-74; PMID:14684272; http://dx.doi.org/10.1016/j.jconrel.2003.09.010. 132. Paukner S, Kudela P, Kohl G, Schlapp T, Friedrichs S, Lubitz W. DNA-loaded bacterial ghosts efficiently mediate reporter gene transfer and expression in macro- phages. Mol Ther 2005; 11:215-23; PMID:15668133; http://dx.doi.org/10.1016/j.ymthe.2004.09.024. 133. Lubitz P, Mayr UB, Lubitz W. Applications of bac- terial ghosts in biomedicine. Adv Exp Med Biol 2009; 655:159-70; PMID:20047041; http://dx.doi. org/10.1007/978-1-4419-1132-2_12. 134. Burke B, Tang N, Corke KP, Tazzyman D, Ameri K, Wells M, et al. Expression of HIF-1alpha by human macrophages: implications for the use of macrophages in hypoxia-regulated cancer gene therapy. J Pathol 2002; 196:204-12; PMID:11793372; http://dx.doi. org/10.1002/path.1029. 135. Burke B, Sumner S, Maitland N, Lewis CE. Macrophages in gene therapy: cellular delivery vehicles and in vivo targets. J Leukoc Biol 2002; 72:417-28; PMID:12223508. 136. Dou H, Grotepas CB, McMillan JM, Destache CJ, Chaubal M, Werling J, et al. Macrophage deliv- ery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J Immunol 2009; 183:661-9; PMID:19535632; http://dx.doi. org/10.4049/jimmunol.0900274. 870 rNA Biology volume 9 issue 6